In NSCLC, CD147-K234me2—a di-methylated variant of CD147 at Lys-234 catalyzed by lysine methyltransferase 5A (KMT5A)—enhances glycolytic flux and lactate export, thereby promoting tumor progression (78). Here, KMT5A is linked to neoplasm.